Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
Global regulatory affairs leader with 30 years in the pharmaceutical industry, including 28 years in regulatory affairs spanning development, registration, and lifecycle management Most recently led FDA interactions as Senior Director, Regulatory Affairs (Rare Diseases) at Insmed;...
Covered in this story
Analyst targets on Insmed
- Goldman Sachs: $122 → $188 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INSM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Insmed →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.